Datamonitor's October edition of the Cardiovascular Review brings you the latest news, analysis and research in the cardiovascular industry.

It covers all the major current business issues, ranging from R&D, licensing deals, alliances and joint ventures, and regulatory decisions.

Scope

• Strategic insight into the future shape of cardiovascular companies and markets

• The most significant cardiovascular industry news compiled into one monthly update

• Expert analysis into the implications of the month's important cardiovascular industry events

• Insight into the future shape of the market for players at all levels

• All the month's cardiovascular stories in headline and summary form

Report Highlights

Out of the dozens of topics covered in this month's review, the most important include:

* AstraZeneca insisted that its cholesterol-lowering drug, Crestor is more effective across a wide range of doses than Pfizer's Lipitor, its key rival.

* Aventis has found that Clexane/Lovenox, its antithrombotic drug, may be a more cost-effective method to prevent blood coagulation when looking to re-establish normal heart rhythms.

Reasons to Purchase

• Not only keeps you updated about industry events - it also gives you opinion and insight

• Draws upon Datamonitor analysts' extensive experience to bring you our perspective on the impact of the latest events

• Provides you with your own news archive to track company and industry progress, giving you an extensive reference to relevant events and issues

R&D UPDATE: CARDIAC DISEASE

The most significant news in cardiac disease R&D, compiled into one monthly update.

R&D UPDATE: HYPERLIPIDEMIA

The most significant news in hyperlipidemia R&D, compiled into one monthly update.

R&D UPDATE: HYPERTENSION

The most significant news in hypertension R&D, compiled into one monthly update.

R&D UPDATE: OTHER CARDIO

The most significant news in other cardio R&D, compiled into one monthly update.

• Thrombosis

• Anemia

• Arrhythmia

LATEST COMMENT

Expert analysis of the implications of the month's important industry events

• Sankyo: stretching Benicar further

• Lilly: no European rebirth for Xigris

• Johnson & Johnson: Cypher stent set to hit the US

NEWS HEADLINES - CARDIAC DISEASE

All the month's cardiac disease news stories in headline and summary form

NEWS HEADLINES - HYPERTENSION

All the month's hypertension news stories in headline and summary form

NEWS HEADLINES - HYPERLIPIDEMIA

All the month's hyperlipidemia news stories in headline and summary form

NEWS HEADLINES - OTHER CARDIO

All the month's other cardio news stories in headline and summary form

To order - click here!